1. Market Research
  2. > Neuralgia – Pipeline Review, H1 2013

Neuralgia – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 473 pages

Neuralgia – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Neuralgia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuralgia. Neuralgia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuralgia.
- A review of the Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuralgia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neuralgia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuralgia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Neuralgia - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
Introduction 7
Neuralgia Overview 8
Therapeutics Development 9
Neuralgia Therapeutics under Development by Companies 11
Neuralgia Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Mid Clinical Stage Products 23
Early Clinical Stage Products 24
Discovery and Pre-Clinical Stage Products 25
Neuralgia Therapeutics - Products under Development by Companies 26
Neuralgia Therapeutics - Products under Investigation by Universities/Institutes 38
Companies Involved in Neuralgia Therapeutics Development 39
Neuralgia - Therapeutics Assessment 135
Drug Profiles 143
Neuralgia Therapeutics - Drug Profile Updates 377
Neuralgia Therapeutics - Discontinued Products 430
Neuralgia Therapeutics - Dormant Products 436
Neuralgia - Product Development Milestones 445
Appendix 452



List of Tables

Number of Products Under Development for Neuralgia, H1 2013 29
Products under Development for Neuralgia - Comparative Analysis, H1 2013 30
Number of Products under Development by Companies, H1 2013 32
Number of Products under Investigation by Universities/Institutes, H1 2013 41
Comparative Analysis by Late Stage Development, H1 2013 42
Comparative Analysis by Mid Clinical Stage Development, H1 2013 43
Comparative Analysis by Early Clinical Stage Development, H1 2013 44
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 45
Products under Development by Companies, H1 2013 46
Products under Investigation by Universities/Institutes, H1 2013 58
Bristol-Myers Squibb Company, H1 2013 59
Genzyme Corporation, H1 2013 60
DURECT Corporation, H1 2013 61
Kyowa Hakko Kirin Co., Ltd., H1 2013 62
Biogen Idec Inc., H1 2013 63
Allergan, Inc., H1 2013 64
Shionogi and Co., Ltd., H1 2013 65
Sanofi-Aventis, H1 2013 66
AstraZeneca PLC, H1 2013 67
BioDelivery Sciences International, Inc., H1 2013 68
GlaxoSmithKline plc, H1 2013 69
Nektar Therapeutics, H1 2013 70
MedImmune LLC, H1 2013 71
Quark Pharmaceuticals, Inc., H1 2013 72
Daiichi Sankyo Company, Ltd, H1 2013 73
Merck and Co., Inc., H1 2013 74
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 75
Sangamo BioSciences, Inc., H1 2013 76
XenoPort, Inc., H1 2013 77
BioLineRx, Ltd., H1 2013 78
Samyang Corporation, H1 2013 79
Astellas Pharma Inc., H1 2013 80
Daewoong Pharmaceutical Co., Ltd., H1 2013 81
Esteve Group, H1 2013 82
Glenmark Pharmaceuticals Ltd., H1 2013 83
LEO Pharma A/S, H1 2013 84
Pfizer Inc., H1 2013 85
Sigma-Tau S.p.A., H1 2013 86
Teva Pharmaceutical Industries Limited, H1 2013 87
Sun Pharmaceutical Industries Limited, H1 2013 88
Vernalis plc, H1 2013 89
Merck KGaA, H1 2013 90
EpiCept Corporation, H1 2013 91
Evotec Aktiengesellschaft, H1 2013 92
GW Pharmaceuticals plc, H1 2013 93
Anavex Life Sciences Corp., H1 2013 94
IntelGenx Technologies Corp., H1 2013 95
AVANIR Pharmaceuticals, H1 2013 96
Lpath, Inc., H1 2013 97
Medivir AB, H1 2013 98
Benitec Ltd., H1 2013 99
NeurogesX, Inc., H1 2013 100
Nuvo Research Inc., H1 2013 101
CombinatoRx, Incorporated, H1 2013 102
Torrent Pharmaceuticals Limited, H1 2013 103
Diamyd Medical AB, H1 2013 104
Transition Therapeutics Inc., H1 2013 105
Neurim Pharmaceuticals (1991) Ltd., H1 2013 106
Pluristem Therapeutics Inc., H1 2013 107
DARA BioSciences, Inc., H1 2013 108
Proximagen Neuroscience plc., H1 2013 109
Newron Pharmaceuticals S.p.A., H1 2013 110
Debiopharm Group, H1 2013 111
Auspex Pharmaceuticals, H1 2013 112
VistaGen Therapeutics , Inc., H1 2013 113
BCN Peptides S.A., H1 2013 114
Palau Pharma S.A, H1 2013 115
Snowdon Inc., H1 2013 116
Neurotune AG, H1 2013 117
Grunenthal GmbH, H1 2013 118
Xenon Pharmaceuticals Inc., H1 2013 119
CREABILIS Therapeutics S.r.l., H1 2013 120
Amura Holdings Ltd., H1 2013 121
Affectis Pharmaceuticals AG, H1 2013 122
AngioChem Inc., H1 2013 123
PharmEste, H1 2013 124
WEX Pharmaceuticals Inc., H1 2013 126
Hydra Biosciences, Inc., H1 2013 127
Yaupon Therapeutics, Inc., H1 2013 128
NeurAxon, Inc., H1 2013 129
Virobay Inc., H1 2013 130
Concert Pharmaceuticals, Inc., H1 2013 131
QRxPharma Limited, H1 2013 132
Cara Therapeutics, Inc., H1 2013 133
Intellipharmaceutics International Inc., H1 2013 134
K.U.Leuven Research and Development, H1 2013 135
KYORIN Pharmaceutical Co., Ltd., H1 2013 136
to-BBB technologies BV, H1 2013 137
Lipopharma, H1 2013 138
Winston Pharmaceuticals, Inc., H1 2013 139
Medisyn Technologies, Inc., H1 2013 140
Maruho Co.,Ltd., H1 2013 141
NeuroTherapeutics Pharma Inc., H1 2013 142
Bial - Portela and Ca, S.A., H1 2013 143
CLL Pharma, H1 2013 144
Beijing Tide Pharmaceutical Co., Ltd., H1 2013 145
Inserm Transfert SA, H1 2013 146
Spinifex Pharmaceuticals Pty Limited, H1 2013 147
TheraQuest Biosciences, LLC, H1 2013 148
Celtic Pharmaceutical Holdings L.P., H1 2013 149
Vichem Chemie Research Ltd., H1 2013 150
RaQualia Pharma Inc., H1 2013 151
Mt Cook Pharma. Inc., H1 2013 152
Naurex, Inc., H1 2013 153
Cytogel Pharma, LLC, H1 2013 154
Assessment by Monotherapy Products, H1 2013 155
Assessment by Combination Products, H1 2013 156
Assessment by Stage and Route of Administration, H1 2013 159
Assessment by Stage and Molecule Type, H1 2013 162
Neuralgia Therapeutics - Drug Profile Updates 397
Neuralgia Therapeutics - Discontinued Products 450
Neuralgia Therapeutics - Dormant Products 456



List of Figures

Number of Products under Development for Neuralgia, H1 2013 29
Products under Development for Neuralgia - Comparative Analysis, H1 2013 30
Products under Development by Companies, H1 2013 31
Products under Investigation by Universities/Institutes, H1 2013 40
Late Stage Products, H1 2013 42
Mid Clinical Stage Products, H1 2013 43
Early Clinical Stage Products, H1 2013 44
Discovery and Pre-Clinical Stage Products, H1 2013 45
Assessment by Monotherapy Products, H1 2013 155
Assessment by Combination Products, H1 2013 156
Assessment by Route of Administration, H1 2013 157
Assessment by Stage and Route of Administration, H1 2013 158
Assessment by Molecule Type, H1 2013 160
Assessment by Stage and Molecule Type, H1 2013 161

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.